Stemline Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older. It also developing CD123 that is in Phase I/II clinical trials for the treatment of chronic myelomonocytic leukemia and myelofibrosis, as well as acute myeloid leukemia and multiple myeloma in combination with other therapies. In addition, the company is developing SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trials to treat brain cancer. Its preclinical pipeline products include SL-501, a CD123 targeted therapy; SL- 1001, an oral, selective small molecule RET kinase inhibitor targeting multiple oncology indications; and SL-901, a small molecule kinase inhibitor. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone646-502-2311
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$500,000.00
Profitability
Miscellaneous
Employees92
Next Earnings Date8/8/2019 (Estimated)
OptionableOptionable
Stemline Therapeutics (NASDAQ:STML) Frequently Asked Questions
What is Stemline Therapeutics' stock symbol?
Stemline Therapeutics trades on the NASDAQ under the ticker symbol "STML."
How were Stemline Therapeutics' earnings last quarter?
Stemline Therapeutics Inc (NASDAQ:STML) announced its quarterly earnings results on Friday, May, 10th. The biopharmaceutical company reported ($0.73) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.67) by $0.06. The biopharmaceutical company had revenue of $5.05 million for the quarter, compared to the consensus estimate of $2.61 million. View Stemline Therapeutics' Earnings History.
When is Stemline Therapeutics' next earnings date?
What price target have analysts set for STML?
6 brokers have issued 1-year price objectives for Stemline Therapeutics' stock. Their predictions range from $17.00 to $35.00. On average, they expect Stemline Therapeutics' share price to reach $25.20 in the next twelve months. This suggests a possible upside of 72.1% from the stock's current price. View Analyst Price Targets for Stemline Therapeutics.
What is the consensus analysts' recommendation for Stemline Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stemline Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Stemline Therapeutics.
What are Wall Street analysts saying about Stemline Therapeutics stock?
Here are some recent quotes from research analysts about Stemline Therapeutics stock:
- 1. According to Zacks Investment Research, "Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York. " (3/5/2019)
- 2. HC Wainwright analysts commented, "Our 12-month price target is derived from a discounted cash flow based asset value of $1.46B for 15% discount rate and 2% terminal growth rate. The company has approximately 42M shares outstanding after the recent financing. Probabilities of market entry ascribed to SL-401 and SL-701 are 100% and 45%, respectively." (1/25/2019)
Has Stemline Therapeutics been receiving favorable news coverage?
Media stories about STML stock have been trending negative this week, InfoTrie reports. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Stemline Therapeutics earned a media sentiment score of -2.7 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the company's share price in the next few days.
Who are some of Stemline Therapeutics' key competitors?
Some companies that are related to Stemline Therapeutics include Arena Pharmaceuticals (ARNA), Intercept Pharmaceuticals (ICPT), The Medicines (MDCO), Uniqure (QURE), PTC Therapeutics (PTCT), Myokardia (MYOK), Emergent Biosolutions (EBS), Ligand Pharmaceuticals (LGND), Arrowhead Pharmaceuticals (ARWR), Insmed (INSM), Portola Pharmaceuticals (PTLA), Akcea Therapeutics (AKCA), Endocyte (ECYT), Allakos (ALLK) and AnaptysBio (ANAB).
What other stocks do shareholders of Stemline Therapeutics own?
Who are Stemline Therapeutics' key executives?
Stemline Therapeutics' management team includes the folowing people:
- Dr. Ivan Bergstein, Founder, Pres, CEO & Chairman (Age 53)
- Mr. David G. Gionco, VP of Fin. & Chief Accounting Officer (Age 59)
- Mr. Kenneth Hoberman, COO & Corp. Sec. (Age 54)
- Mr. Robert Francomano, Sr. VP & Global Head of Commercial
- Mr. John A. Salvagno, Sr. VP of Quality & Operations
Who are Stemline Therapeutics' major shareholders?
Stemline Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Rubric Capital Management LP (6.90%), BlackRock Inc. (6.21%), Goldman Sachs Group Inc. (3.12%), The Manufacturers Life Insurance Company (2.79%), FMR LLC (2.10%) and Schonfeld Strategic Advisors LLC (1.79%). Company insiders that own Stemline Therapeutics stock include David Gionco, Ivan Bergstein and Kenneth Hoberman. View Institutional Ownership Trends for Stemline Therapeutics.
Which major investors are selling Stemline Therapeutics stock?
STML stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Citigroup Inc., Morgan Stanley, Jacobs Levy Equity Management Inc., JPMorgan Chase & Co. and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have sold Stemline Therapeutics company stock in the last year include David Gionco, Ivan Bergstein and Kenneth Hoberman. View Insider Buying and Selling for Stemline Therapeutics.
Which major investors are buying Stemline Therapeutics stock?
STML stock was acquired by a variety of institutional investors in the last quarter, including Rubric Capital Management LP, Goldman Sachs Group Inc., Schonfeld Strategic Advisors LLC, BlackRock Inc., Man Group plc, C WorldWide Group Holding A S, Pier Capital LLC and Fosun International Ltd. View Insider Buying and Selling for Stemline Therapeutics.
How do I buy shares of Stemline Therapeutics?
Shares of STML can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Stemline Therapeutics' stock price today?
One share of STML stock can currently be purchased for approximately $14.64.
How big of a company is Stemline Therapeutics?
Stemline Therapeutics has a market capitalization of $639.55 million and generates $500,000.00 in revenue each year. The biopharmaceutical company earns $-85,020,000.00 in net income (profit) each year or ($2.99) on an earnings per share basis. Stemline Therapeutics employs 92 workers across the globe.
What is Stemline Therapeutics' official website?
How can I contact Stemline Therapeutics?
Stemline Therapeutics' mailing address is 750 LEXINGTON AVENUE ELEVENTH FLOOR, NEW YORK NY, 10022. The biopharmaceutical company can be reached via phone at 646-502-2311 or via email at [email protected]
MarketBeat Community Rating for Stemline Therapeutics (NASDAQ STML)
MarketBeat's community ratings are surveys of what our community members think about Stemline Therapeutics and other stocks. Vote "Outperform" if you believe STML will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STML will underperform the S&P 500 over the long term. You may vote once every thirty days.
